FDMT
NASDAQ · Biotechnology
4D Molecular Therapeutics In
$10.75
+0.20 (+1.90%)
Open$10.66
Previous Close$10.55
Day High$10.84
Day Low$10.45
52W High$14.00
52W Low$5.33
Volume—
Avg Volume553.3K
Market Cap561.97M
P/E Ratio—
EPS$-2.70
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+96.4% upside
Current
$10.75
$10.75
Target
$21.11
$21.11
$12.84
$21.11 avg
$26.25
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 81.20M | 286.9K | 228.58M |
| Net Income | -133,514,726 | -1,099,890,361 | -57,732,834 |
| Profit Margin | -164.4% | -413,039.5% | -25.3% |
| EBITDA | -147,563,969 | -1,322,641,633 | -107,016,126 |
| Free Cash Flow | — | — | -89,291,698 |
| Rev Growth | +200.8% | -87.3% | +10.3% |
| Debt/Equity | — | — | 0.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |